192 related articles for article (PubMed ID: 1703260)
1. Antimuscarinic potency and functional selectivity of oxotremorine analogs at muscarinic receptor subtypes in the rat.
Vargas HM; Ringdahl B
Life Sci; 1990; 47(22):2065-73. PubMed ID: 1703260
[TBL] [Abstract][Full Text] [Related]
2. Centrally active antimuscarinic analogs of oxotremorine selectively block physostigmine-induced hypertension, but not peripheral muscarinic vasodepression.
Vargas HM; Ringdahl B
J Pharmacol Exp Ther; 1990 Apr; 253(1):165-70. PubMed ID: 2329503
[TBL] [Abstract][Full Text] [Related]
3. Muscarinic receptor subtypes and sexual behavior in female rats.
Dohanich GP; McMullan DM; Cada DA; Mangum KA
Pharmacol Biochem Behav; 1991 Jan; 38(1):115-24. PubMed ID: 1708147
[TBL] [Abstract][Full Text] [Related]
4. Muscarinic receptor agonist-mediated modulation of neuronal activity in rat cerebral cortex.
Lin Y; Phillis JW
Eur J Pharmacol; 1991 Jul; 200(1):45-52. PubMed ID: 1722754
[TBL] [Abstract][Full Text] [Related]
5. M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors.
Schoffelmeer AN; Hogenboom F; Mulder AH
J Pharmacol Exp Ther; 1988 May; 245(2):658-63. PubMed ID: 2452877
[TBL] [Abstract][Full Text] [Related]
6. Postsynaptic integration of cholinergic and dopaminergic signals on medium-sized GABAergic projection neurons in the neostriatum.
Harsing LG; Zigmond MJ
Brain Res Bull; 1998 Apr; 45(6):607-13. PubMed ID: 9566505
[TBL] [Abstract][Full Text] [Related]
7. Presynaptic muscarinic receptors mediating inhibition of neurogenic contractions in rabbit vas deferens are of the ganglionic M1-type.
Eltz M; Gmelin G; Wess J; Strohmann C; Tacke R; Mutschler E; Lambrecht G
Eur J Pharmacol; 1988 Dec; 158(3):233-42. PubMed ID: 2472963
[TBL] [Abstract][Full Text] [Related]
8. M2 muscarinic receptor agonists produce hypotension and bradycardia when injected into the nucleus tractus solitarii.
Sundaram K; Murugaian J; Watson M; Sapru H
Brain Res; 1989 Jan; 477(1-2):358-62. PubMed ID: 2467726
[TBL] [Abstract][Full Text] [Related]
9. Effect of specific M1, M2 muscarinic receptor agonists on REM sleep generation.
Velazquez-Moctezuma J; Gillin JC; Shiromani PJ
Brain Res; 1989 Nov; 503(1):128-31. PubMed ID: 2482113
[TBL] [Abstract][Full Text] [Related]
10. The relative potencies of cholinomimetics and muscarinic antagonists on the rat iris in vivo: effects of pH on potency of pirenzepine and telenzepine.
Hagan JJ; van der Heijden B; Broekkamp CL
Naunyn Schmiedebergs Arch Pharmacol; 1988 Nov; 338(5):476-83. PubMed ID: 3244389
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of central administration of cholinomimetics in anesthetized cats.
Ally A; Hara Y; Murayama S
Neuropharmacology; 1993 Feb; 32(2):185-93. PubMed ID: 7680786
[TBL] [Abstract][Full Text] [Related]
12. Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1985 Mar; 232(3):608-16. PubMed ID: 2579230
[TBL] [Abstract][Full Text] [Related]
13. Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine.
Giachetti A; Giraldo E; Ladinsky H; Montagna E
Br J Pharmacol; 1986 Sep; 89(1):83-90. PubMed ID: 2432979
[TBL] [Abstract][Full Text] [Related]
14. Muscarinic receptor-mediated phosphoinositide hydrolysis in the rat retina.
Moroi-Fetters SE; Neff NH; Hadjiconstantinou M
J Pharmacol Exp Ther; 1988 Aug; 246(2):553-7. PubMed ID: 2841451
[TBL] [Abstract][Full Text] [Related]
15. Effect of extracellular calcium concentration on potency of muscarinic agonists at M1 and M2 receptors in rabbit vas deferens.
Dörje F; Rettenmayr NM; Mutschler E; Lambrecht G
Eur J Pharmacol; 1991 Oct; 203(3):417-20. PubMed ID: 1723047
[TBL] [Abstract][Full Text] [Related]
16. Amide, urea, and carbamate analogues of the muscarinic agent [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride.
Nilsson BM; Vargas HM; Hacksell U
J Med Chem; 1992 Jul; 35(15):2787-98. PubMed ID: 1379640
[TBL] [Abstract][Full Text] [Related]
17. Central muscarinic M2 cholinoceptors involved in cholinergic hypertension.
Ozkutlu U; Onat F; Aslan AN; Oktay S
Eur J Pharmacol; 1993 Dec; 250(3):349-54. PubMed ID: 8112394
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic M1 receptors in the lateral septal area mediate cardiovascular responses to cholinergic agonists and bradykinin: supersensitivity induced by chronic treatment with atropine.
Scheucher A; Pirola CJ; Balda MS; Dabsys SM; Alvarez AL; Finkielman S; Nahmod VE
Neuropharmacology; 1987; 26(2-3):181-5. PubMed ID: 2438581
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic M1 receptor activation reduces maximum upstroke velocity of action potential in mouse right atria.
Islam MA; Nojima H; Kimura I
Eur J Pharmacol; 1998 Apr; 346(2-3):227-36. PubMed ID: 9652364
[TBL] [Abstract][Full Text] [Related]
20. Evidence that reciprocal hindlimb scratching elicited in mice by intrathecal administration of muscarinic agonists is mediated through M1 type receptors.
Raffa RB; Mathiasen JR; Goode TL; Vaught JL
Life Sci; 1987 Oct; 41(15):1831-6. PubMed ID: 2443784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
